博瑞医药前三季度净利5032万元，同比下降71.64%

Core Viewpoint - 博瑞医药 reported a significant decline in both revenue and net profit for the first three quarters of 2025, primarily due to changes in flu trends and competitive landscape affecting the demand and pricing of antiviral products [1] Financial Performance - The company's revenue for the first three quarters was 874 million yuan, representing a year-on-year decrease of 10.5% [1] - The net profit attributable to shareholders was 50.32 million yuan, down 71.64% compared to the same period last year [1] Product Performance - The demand and pricing for oseltamivir raw materials and formulations decreased, leading to a substantial reduction in revenue and gross profit for antiviral products [1] - A decline in sales of antifungal raw materials was noted, attributed to fluctuations in customer demand and product pricing, resulting in a significant drop in gross profit for this category [1]